US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: New and larger shareholders back SynAct's capital raise - CEO comments

SynAct Pharma has announced a capital raise of approximately SEK 65 million. The funding, subject to approval by an extraordinary general meeting, will be achieved through a combination of directed issues and a fully guaranteed rights issue. This initiative is supported by some of the company's larger shareholders and will fund the continued development of resomelagon in rheumatoid arthritis, for which the company just received EU trial approval for its phase IIb ADVANCE study.Read the full article at biostock.se :https://www.biostock.se/en/2024/11/new-and-

SynAct Pharma’s Chairman to BioStock: ”We are confident we have the right strategy”

SynAct Pharma’s Capital Markets Day provided detailed information regarding the revised strategy for its lead asset, resomelagon. The company focuses on the phase IIb ADVANCE study in early, severe rheumatoid arthritis, which is now up and running in the US. In parallel, the company is engaging in partnering discussions to strike a deal for phase III studies and beyond.– SynAct has a clear strategy, the right team and fresh funding to continue with its plan, says Anders Kronborg, Chairman of the Board.Read the full article at biostock.se : https://www.

BioStock: SynAct Pharma moves forward with filing process

Following previous studies in rheumatoid arthritis, SynAct Pharma knows much more about the possibilies and requirements for assessing resomelagon’s effect. The company is now acting on its strategy by initiating the filing process for a new clinical phase IIb study with resomelagon in patients with severe, newly diagnosed RA with signs of systemic inflammation. BioStock reached out to CEO Jeppe Øvlesen to learn more about the clinical trial, named ADVANCE.Read the full article at biostock.se : https://www.biostock.se/en/2024/07/synact-pharma-moves-forward-

BioStock: SynAct Pharma’s CEO provides an update

SynAct Pharma has signed a contract with a CRO and aims to submit a Clinical Trial Application this quarter for the upcoming clinical phase IIb study with resomelagon. Furthermore, the company has conducted a capital raise of SEK 49 million, and the new board and management team are working to reduce costs.– Together, the new team is more focused and ready to move fast, says CEO Jeppe Øvlesen.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/synact-pharmas-ceo-provides-an-update/ This is a press release from BioStock - Connecting

BioStock: Synact focuses on pushing forward rheumatoid arthritis project

SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting a directed share issue of SEK 49.2 million to develop resomelagon further in rheumatoid arthritis. BioStock got in touch with Synact’s CSO Thomas Jonassen to learn more.Read the article at biostock.se: https://www.biostock.se/en/2024/04/synact-focuses-on-pushing-forward-rheumatoid-arthritis-project/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Synact’s new CEO to BioStock: “I’m hitting the ground running”

On March 20, SynAct Pharma convened an Extraordinary General Meeting, resulting in a new composition of the Board of Directors. Additionally, Jeppe Øvlesen is regaining the position as CEO with the aim to get the company “back on track”. BioStock reached out to Jeppe and CSO Thomas Jonassen to learn more about the changes and strategic direction.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/synacts-new-ceo-i-am-hitting-the-ground-running/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock: Deep dive into SynAct Pharma’s new strategy

With support from leading rheumatologists, SynAct Pharma is presenting a reshaped strategic plan for resomelagon in rheumatoid arthritis. In addition, they are planning to initiate a phase II trial with resomelagon in influenza patients and prepare the melanocortin agonist TXP-11 for clinical development. BioStock reached out to CEO Torbjørn Bjerke to learn more about the new strategic plan.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/deep-dive-into-synact-pharmas-new-strategy/ This is a press release from BioStock - Connecting

BioStock: SynAct Pharma raises 60,5 MSEK through a directed share issue

Biotech company SynAct Pharma has decided to carry out a directed share issue of approximately 60,5 Mkr to an entity managed by Heights Capital Management. The funding enables the continued development of their primary drug candidate resomelagon. The capital will also be used for business development activites.Read the full article at biostock.se: https://www.biostock.se/en/2023/10/synact-pharma-raises-605-msek-through-a-directed-share-issue/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Positive subgroup data in SynAct Pharmas’s EXPAND study

Biotech SynAct Pharma has unveiled additional data from its EXPAND phase II clinical trial with resomelagon for rheumatoid arthritis. The new findings indicate consistent responsiveness to the drug candidate in a sub-population of patients with c-reactive protein level exceeding 3 mg/L, which is an indicative for active systemic inflammation. These encouraging findings are important for further development of resomelagon, according to the company’s CSO Thomas Jonassen in an interview.Read the full article at biostock.se: https://www.biostock.se/en/2023/09/positive-subgroup-data-in-synact-

BioStock: SynAct Pharma’s CEO comments on EXPAND data

SynAct Pharma has announced disappointing top-line data from its 12-week EXPAND phase IIb clinical trial. The study is evaluating the drug candidate resomelagon in newly diagnosed rheumatoid arthritis patients with severe disease. Results show a high placebo effect thus not achieving the primary endpoint – a statistically higher rate of 20 improvement in the American College of Rheumatology score compared to placebo. BioStock spoke to CEO Torbjørn Bjerke about the results.Read the full article at biostock.se: https://www.biostock.se/en/2023/09/synact-pharmas-ceo-comments-on-expand-data/

BioStock: SynAct Pharma’s CEO comments on the recent progress

SynAct Pharma recently achieved a milestone by completing dosing in the Phase IIb EXPAND study for resomelagon (AP1189), their candidate targeting rheumatoid arthritis. In addition, the company has now also successfully recruited all patients for part A of the Phase IIa/b RESOLVE study. To delve deeper into these developments, BioStock contacted SynAct Pharma’s CEO, Torbjørn Bjerke, for a comment.Read the full interview with Torbjørn Bjerke at biostock.se: https://www.biostock.se/en/2023/07/synact-pharmas-ceo-comments-on-the-recent-progress/ This is a press release from BioStock -

BioStock: Highlights from SynAct Pharma’s Capital Markets Day

On May 5, SynAct Pharma held a Capital Markets Day in Stockholm featuring presentations from the management team, as well as Key Opinion Leaders in inflammation resolution and rheumatoid arthritis. The presentations highlighted the unmet medical need in rheumatoid arthritis and validated the potential of SynAct Pharma’s drug candidate resomelagon in that area, but also in other diseases characterised by inflammation. BioStock contacted Torbjørn Bjerke to hear his highlights from the day.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/highlights-from-synact-

BioStock: SynAct completes patient recruitment ahead of schedule

SynAct Pharma has completed the patient recruitment to the phase IIb trial EXPAND with resomelagon (AP1189) in newly diagnosed, severe rheumatoid arthritis. The last patient was enrolled well ahead of schedule, enabling reporting of top-line data in about five months. The company’s CSO Thomas Jonassen commented on the progress to BioStock.Read the full article at biostock.se: https://www.biostock.se/en/2023/04/synact-completes-patient-recruitment-ahead-of-schedule/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Synact Pharma about the changes in the company

Biotech company Synact Pharma visited BioStock's studio to talk about changes in the management and board. With upcoming phase II data during the autumn 2023, the company will focus more on business development. As a consequence, the current chairman Torbjørn Bjerke takes over as CEO when Jeppe Øvlesen steps down at the annual general meeting in May.Watch the full video interview with SynAct Pharma at biostock.se:  https://www.biostock.se/en/2023/04/synact-pharma-about-the-changes-in-the-company/ This is a press release from BioStock – Connecting Innovation & Capital. https://www.

BioStock: SynAct Pharma announces change in management

The biotech company SynAct Pharma has important clinical data coming in 2023 and recently expanded its portfolio with the acquisition of TXP Pharma. SynAct is now making a switch in management to focus more on business development. Current Chairman Torbjørn Bjerke will take over as CEO as Jeppe Øvlesen steps down. Synact also proposes changes in the board with the current member Uli Hacksell as the new Chairman and Thomas von Koch as a board member.Read the article about SynAct Pharma at biostock.se: https://www.biostock.se/en/2023/04/synact-pharma-announces-change-in-management/ This

BioStock: Progress for SynAct Pharma in 2022 – more milestones ahead

SynAct Pharma recently published the year-end report for 2022, presenting great progress in its pipeline with the lead compound AP1189. Now they have another exciting and crucial year ahead of them with several data read-outs from the three clinical trials with AP1189. Following the acquisition of TXP Pharma, they also have a substantially expanded portfolio of melanocortin peptides to explore.Read the full article at biostock.se: https://www.biostock.se/en/2023/02/progress-for-synact-pharma-in-2022-more-milestones-ahead/ This is a press release from BioStock - Connecting Innovation &

BioStock: SynAct Pharma’s acquisition of TXP Pharma concluded

Just before the end of 2022, SynAct Pharma announced its plans to acquire the Swiss biotech company TXP Pharma. The acquisition was approved on the Extraordinary General Meeting on January 12 and then completed on January 16. The addition of TXP’s platform puts SynAct Pharma in the forefront of resolution treatment through selective melanocortin stimulation and provides development opportunities in a broad range of autoimmune and inflammatory diseases.Read the full article at biostock.se: https://www.biostock.se/en/2023/01/synact-pharmas-acquisition-of-txp-pharma-concluded/ This is a

BioStock: SynAct Pharma's CSO comments approved IND and Q3

SynAct Pharma has received IND approval from the FDA, meaning that they can initiate the phase IIa/b RESOLVE study of AP1189 in DMARD-IR patients. They have also just published their report for the third quarter, a busy period with significant progress in the development programmes with AP1189. CSO Thomas Jonassen visited BioStock's studio to talk about the IND approval, patient recruitment in the EXPAND study, financing, and partnering discussions.Watch the interview with SynAct Pharma's CSO Thomas Jonassen at biostock.se: https://www.biostock.se/en/2022/11/synact-pharmas-cso-comments-

BioStock: SynAct submits IND and recruits first patient

SynAct Pharma is well in line with the communicated plans for the two phase II trials with AP1189 in rheumatoid arthritis – EXPAND and RESOLVE. Most importantly, an IND application has been submitted to the FDA to initiate the RESOLVE study in the US in patients with incomplete response to DMARDs. Another milestone was the enrollment of the first patient in EXPAND, a clinical phase IIb study to investigate the full treatment potential of AP1189 in patients with newly diagnosed rheumatoid arthritis.Read the full article at biostock.se: https://www.biostock.se/en/2022/10/synact-submits-ind-

BioStock: SynAct comments on the revision of nephrology study

In July, SynAct Pharma applied for an amendment of the ongoing phase IIa study with AP1189 in patients with idiopathic membranous nephropathy (iMN). In the new study format, the dosing duration is increased from four weeks to three months and the new AP1189 tablet is used. The protocol amendment has now been approved by the Danish Medicines Agency and is currently being assessed in Sweden and Norwary. BioStock talked to CSO Thomas Jonassen.Read the full article at biostock.se: https://www.biostock.se/en/2022/09/synact-comments-on-the-revision-of-nephrology-study/ This is a press

BioStock: SynAct Pharma summarises busy second quarter

SynAct Pharma's CEO Jeppe Øvlesen and CFO Patrik Renblad visit BioStock's studio to talk about the second quarter report, the uplisting to Nasdaq Stockholm Main Market and the new design for the phase IIa study with AP1189 in idiopathic membranous nephropathy (iMN). In addition, we get to know more about the company's main focus this fall and how long the current cash position will finance the development activities.Watch the video interview with SynAct Pharma’s CEO and CFO at biostock.se: https://www.biostock.se/en/2022/08/synact-pharma-summarises-busy-second-quarter 

SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm

SynAct Pharma AB (“SynAct” or the “Company”) announced on June 28, 2022 that Nasdaq Stockholm’s listing committee has approved that the company’s shares are admitted to trading on Nasdaq Stockholm Main Market. The prospectus that has been prepared in connection with the list change has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is now available on SynAct’s website, www.synactpharma.com, and will be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.A listing of the Company’s shares on Nasdaq

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe